As with many other markets for medical devices, therapy systems for benign uterine conditions have been negatively impacted by the economic recession and resultant loss of employment/income and subsequent postponement of elective procedures among potential patients. Despite a sluggish economy, however, growth in this segment is expected to accelerate at a low to moderate pace throughout the forecast period, as the market benefits from continued favorable clinical outcomes and the adoption of next-generation therapy systems or instruments that facilitate minimally invasive options and/or safer, more effective, cost-effective treatment of benign uterine conditions. Despite the implementation of the medical device excise tax and reimbursement/pricing challenges, healthcare reform and an increase in the covered female patient population is expected to trend to less invasive/costly options such as hysteroscopic resection and GEA procedures. This market may experience a significant increase in procedures near the end of the forecast period covered by this report (should the economy rebound) due to pent-up demand for elective procedures such as the aforementioned treatments.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include leading benign uterine therapy devices or systems, specifically global endometrial ablation devices, uterine artery embolization systems, hysteroscopes and related products (including new single-insertion hysteroscopic morcellators), and magnetic resonance-guided high-intensity focused ultrasound systems for treating fibroids.
EXECUTIVE SUMMARY i. Overview of Benign Uterine Conditions and Therapies ii. Combined Market Forecast iii. Methodology Exhibit ES-1: U.S. Benign Uterine Conditions Therapy Systems, Combined Market Forecast, 2012-2017 Exhibit ES-2: U.S. Benign Uterine Conditions Therapy Systems, Market Forecast, by Product Segment, 2012-2017 1. OVERVIEW OF TREATMENTS FOR BENIGN UTERINE CONDITIONS 1.1 Dilation and Curettage 1.1.1 Procedure Volumes 1.2 Hysterectomy 1.2.1 Procedure Volumes 1.3 Hysteroscopy 1.3.1 Endometrial Ablation 1.3.2 Procedure Volumes 1.4 Myomectomy 1.4.1 Procedure Volumes Exhibit 1-1: Dilation and Curettage, Procedure Volumes Forecast, 2012-2017 Exhibit 1-2: Hysterectomy, Procedure Volumes Forecast, 2012-2017 Exhibit 1-3: Hysteroscopy, Procedure Volumes Forecast, 2012-2017 Exhibit 1-4: Myomectomy, Procedure Volumes Forecast, 2012-2017 2. GLOBAL ENDOMETRIAL ABLATION DEVICES 2.1 Selected Products 2.1.1 Boston Scientific 2.1.2 CooperSurgical/The Cooper Companies 2.1.3 Ethicon/Johnson & Johnson 2.1.4 Hologic Exhibit 2-1: 2013, Leading Global Endometrial Ablation Products Exhibit 2-2: Three-Step Endometrial Ablation Using the Genesys Hydro ThermAblator System Exhibit 2-3: The Her Option Cryoablation System Exhibit 2-4: The Gynecare ThermaChoice III Uterine Balloon Therapy System in Comparison with Other Thermal Ablation Systems Exhibit 2-5: The NovaSure System and Step-by-Step Endometrial Ablation Process Exhibit 2-6: Selected Features of the Next-Generation NovaSure System 3. MAGNETIC RESONANCE-GUIDED HIGH-INTENSITY FOCUSED ULTRASOUND SYSTEMS 3.1 Products and Procedure 3.1.1 InSightec 184.108.40.206 Clinical Trials 3.1.2 Philips Healthcare/Royal Philips Electronics 220.127.116.11 Clinical Trials Exhibit 3-1: Simple Schematic Illustration of Focused Thermal Energy Technology Exhibit 3-2: Uterine Fibroid Treatment Using the ExAblate System Exhibit 3-3: Sonalleve Therapy 4. UTERINE ARTERY EMBOLIZATION SYSTEMS 4.1 Selected Products 4.1.1 Biocompatibles/BTG International 4.1.2 Boston Scientific 4.1.3 CeloNova BioSciences 4.1.4 Merit Medical Systems 4.2 Embolization versus Focused Ultrasound for Fibroid Treatment Exhibit 4-1: 2013, Selected Embolic Agents Used in Uterine Artery Embolization Exhibit 4-2: CeloNova Biosciences' Embozene Microspheres Exhibit 4-3: Merit Medical Systems' Embosphere Microspheres 5. HYSTEROSCOPES AND RELATED PRODUCTS 5.1 Hysteroscopes and Fibroid Removal Systems 5.1.1 Ethicon/Johnson & Johnson 5.1.2 Gyrus ACMI/Olympus 5.1.3 Hologic 5.1.4 Olympus America/Olympus 5.1.5 Smith & Nephew 5.1.6 KARL STORZ Endoscopy-America/KARL STORZ 5.1.7 Stryker 5.1.8 Richard Wolf Medical Instruments/Richard Wolf 5.2 Uterine Manipulators 5.2.1 ConMed 5.2.2 Cook Medical/Cook Group 5.2.3 Cooper Surgical/The Cooper Companies 5.3 Fluid Management Systems 5.3.1 Davol/C.R. Bard 5.3.2 Gyrus ACMI/Olympus 5.3.3 Hologic 5.3.4 Smith & Nephew 5.3.5 Stryker 5.3.6 Richard Wolf Medical Instruments/Richard Wolf Exhibit 5-1: 2013, Selected Hysteroscopes and Hysteroscopy Fibroid Removal Systems Exhibit 5-2: The Gynecare Versapoint Bipolar Electrosurgery System Exhibit 5-3: The Gynecare Morcellex Tissue Morcellator Exhibit 5-4: The Gynecare Versascope Hysteroscopy System Exhibit 5-5: The PKS PlasmaSORD Bipolar Morcellator Exhibit 5-6: The SlimLine Office and USA Series Continuous Flow Operative Hysteroscopes Exhibit 5-7: The MyoSure Tissue Removal System Exhibit 5-8: The HYF-XP Flexible Hysteroscope Exhibit 5-9: The Truclear Hysteroscopic Morcellator Exhibit 5-10: The Bettocchi Integrated Office Hysteroscope Exhibit 5-11: The Intra-Uterine Bigatti Shaver Exhibit 5-12: The Rotocut G1 Morcellator Exhibit 5-13: The IDEAL EYES HD CST-5000S Flexible Video Hysteroscope Exhibit 5-14: The OptiFLOW Single Sheath Hysteroscope Exhibit 5-15: The BipoTrode Bipolar Electrode Exhibit 5-16: The VCare Vaginal-Cervical Ahluwalia Retractor/Elevator Exhibit 5-17: The Uterine Manipulator Injector Exhibit 5-18: The RUMI Advanced Uterine Manipulation System Exhibit 5-19: The AquaSens Fluid Monitoring System Exhibit 5-20: The Dolphin II Hysteroscopic Fluid Management System Exhibit 5-21: The Aquilex Fluid Control System Exhibit 5-22: The Hysteroscopic Fluid Management System for Hysteroscopic Morcellation Exhibit 5-23: The FluidSafe Fluid Management System 6. U.S. BENIGN UTERINE CONDITIONS THERAPY SYSTEMS MARKET 6.1 Global Endometrial Ablation Devices 6.1.1 Market Forecast 6.1.2 Competitive Analysis 6.2 Uterine Artery Embolization Systems 6.2.1 Market Forecast 6.2.2 Competitive Analysis 6.3 Hysteroscopes and Related Products 6.3.1 Market Forecast 6.3.2 Competitive Analysis 6.3.3 Single-Insertion Hysteroscopic Morcellator Systems 18.104.22.168 Market Forecast 22.214.171.124 Competitive Analysis 6.4 Combined Market Forecast Exhibit 6-1: Global Endometrial Ablation Devices, Market Forecast, 2012-2017 Exhibit 6-2: 2012, Global Endometrial Ablation Device Market, Share by Supplier Exhibit 6-3: Uterine Artery Embolization Systems, Market Forecast, 2012-2017 Exhibit 6-4: 2012, Uterine Artery Embolization Systems Market, Share by Supplier Exhibit 6-5: Hysteroscopes and Related Products, Market Forecast, 2012-2017 Exhibit 6-6: 2012, Hysteroscopes and Related Products Market, Share by Supplier Exhibit 6-7: Single-Insertion Hysteroscopic Morcellator Systems, Market Forecast, 2012-2017 Exhibit 6-8: 2012, Single-Insertion Hysteroscopic Morcellator Systems Market, Share by Supplier Exhibit 6-9: U.S. Benign Uterine Conditions Therapy Systems, Combined Market Forecast, 2012-2017 Exhibit 6-10: U.S. Benign Uterine Conditions Therapy Systems, Market Forecast, by Product Segment, 2012-2017 Exhibit 6-11: 2012, U.S. Benign Uterine Conditions Therapy Systems Market, Share of Sales, by Product Segment Exhibit 6-12: 2017, U.S. Benign Uterine Conditions Therapy Systems Market, Share of Sales, by Product Segment 7. COMPANY PROFILES 7.1 Boston Scientific Corporation 7.2 CeloNova Biosciences, Inc. 7.3 Hologic, Inc. 7.4 InSightec LTD/Elbit Imaging LTD 7.5 Johnson & Johnson 7.6 Philips Healthcare/Royal Philips Electronics NV 7.7 Smith & Nephew PLC 7.8 KARL STORZ GmbH & Co. KG APPENDIX: COMPANY LISTING